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Abstract Acetylcholinesterase inhibitors (AChEIs) 
are widely used in the symptomatic treatment of 
Alzheimer’s disease, a disease that is afflicting a 
major part of our greying population.  Their 
mechanism of action is based upon non-specific 
cholinergic stimulation, thereby potentially 
inducing cardiac beneficial or adverse effects. Data 
of large observational studies demonstrated a small 
but significant cardiac risk for all registered AChEIs 
(donepezil, galantamine and rivastigmine) not 
observed in previous clinical trials. This might be 
explained by a non-selective approach for 
prescribing AChEIs, thereby also including older 
persons with coexisting diseases or using several 
drugs,  opposed to a selective patient recruitment in 
trials. Although there is no consensus on the 
management, we recommend attentiveness for 
cardiac symptoms and heart rhythm in every 
patient treated with AChEIs, and plea for a vigilant 
use of AChEIs in elderly patients at increased risk 
for cardiac adverse effects. 
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Introduction 
For more than a decade now, acetylcholinesterase 
inhibitors (AchEIs) are recommended as a first line 
strategy in the symptomatic treatment of 
Alzheimer’s disease (AD) and related disorders.  
Their mechanism of action is based upon the 
cholinergic hypothesis, alleviating symptoms by 
increasing cholinergic neurotransmission within the 
brain. Because of their nonspecific action 
mechanism, parasympathic side-effects can occur,  
 
and can be of clinical significance, especially in an 
older population suffering multiple comorbidities 
and prone to polypharmacy.    
Cholinergic transmission in normal cognition and 
Alzheimer’s disease 
Cholinergic activity is recognized to be widespread 
in brain areas such as the hippocampus, septum, 
amygdala and neocortex, and crucial for higher 
cognitive functioning. When inhibiting cholinergic 
transmission by administering scopolamine, 
cognitive impairment resembling deficits as seen in 
AD occurs [1].  Postmortem brain autopsies of AD 
patients revealed a drastic reduction of cholinergic 
neurons as well as a reduced acetylcholinesterase 
activity in early affected areas such as the 
hippocampus. These findings led to the cholinergic 
hypothesis of Alzheimer’s disease [2], which opened 
the road for the first approved drug therapies based 
on inhibiting this cholinesterase activity in the brain, 
thereby stimulating cholinergic transmission. 
Development of several compounds including 
tacrine, heptylphysostigmine and metrifonate was 
initiated but their tolerability limited broad clinical 
use [3]. At the end of the last century, the 
cholinesterase inhibitors donepezil, galantamine 
and rivastigmine were approved for market 
authorization for medical treatment for AD and are 
now widely available.  
Mechanism of cholinergic transmission 
Acetylcholine (ACh) is synthesized as a 
neurotransmitter from choline and acetyl-co-
enzyme A, and subsequently stored in and released 
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from synaptic vesicles. It then binds to both pre- 
and postsynaptic nicotinic and muscarinic 
receptors. Nicotinic receptors are pentameric 
excitatory receptors localized in the central nervous 
system, autonomic ganglia, neuromuscular 
junctions and extramedullar glands of which 17 
different subtypes exist [4, 5]. Muscarinic receptors 
are G-protein associated receptors in 5 subtypes: M1 
in the central nervous system (CNS), autonomic 
ganglia and glandular tissue, M2 in the heart, M3 in 
smooth muscle and M4, 5 in the CNS [4]. 
Degradation of ACh is executed by two different 
cholinesterases; acetyl (AChE)- and 
butyrycholinestarase (BuChE).  Where initially a 
predominant role was contributed to AChE, it  now 
appears that both likely play a role in central 
cholinergic transmission [6].  AChE exists in three 
different isoforms, G1 (monomeric), G2 (dimeric) 
and G4 (tetrameric), all occurring in different brain 
areas but with a predominance of the G4 form. 
Isoforms G2 and G4 are also found outside of the 
CNS [7, 8].   
Cognitive and functional effect of AChEIs in AD 
AChEI have been approved for the treatment of 
mild to moderate forms of AD based on the results 
of several trials with the available drugs. They act 
symptomatically without changing the course of the 
disease. They slow down deterioration of cognitive 
and functional decline and can positively affect 
behavioral disorders. Several national and 
international treatment guidelines recommend their 
use as a first line therapy for AD and a Cochrane 
review [9] confirmed their clinical effectiveness 
compared to placebo although effect sizes are 
moderate. As to now, no data support significant 
differences in effectiveness between donepezil, 
galantamine and rivastigmine.  
Safety and tolerability of AChEIs 
In the reported studies, most frequent side effects 
are related to gastrointestinal symptoms, such as 
nausea and vomiting. After a few days tolerance 
often occurs allowing therapy continuation. Several 
other more infrequent side effects have been 
reported as a result from central cholinergic activity 
including dizziness, convulsions, agitation, 
extrapyramidal symptoms and sleeping disorders.  
On the other hand, peripheral cholinergic side 
effects can manifest through diarrhea, rhinorrhea, 
muscle cramps, urinary incontinence or 
cardiorespiratory symptoms. The cardiac effects of 
AChEI therapy will be the further focus of this 
review.  
Donepezil, galantamine and rivastigmine show 
distinct pharmacokinetics 
Pharmacological profiles of registered AChEIs 
differ, leading to potential differential effects on 
cardiac functioning. 
Donepezil 
Donepezil is a quickly reversible AChEI with 
greater affinity for AChE than for BuChE. 
Specificity for the cerebral G1 isoform of AChE is 
relatively low, potentially stimulating peripheral 
cholinergic action, including cardio-inhibitory 
effects [8]. Donepezil is more than 90 %, protein 
bound , and has a half-life of about 3 days. It is 
metabolized by cytochrome P450 (CYP450) 2D6 and 
3A4 and by glucuronidation, making it moderately 
prone to interaction with other drugs [8, 10]. 
Galantamine 
Galantamine is a quickly reversible AChEI as well, 
also with greater affinity for AChE than for BuChE, 
but with a low specificity for the G1 isoform, 
potentially contributing to unwanted peripheral 
side effects [8]. Galantamine binds also to the 
postsynaptic nicotinic receptor thereby stimulating 
cholinergic transmission, but it is not known how 
clinically relevant this stimulation is. Plasma protein 
binding is low (18%) and half-life is 4-6h. It is 
partially metabolized by CYP2D6 and CYP3A4. No 
single pathway seems to be predominant [8, 10].  
Rivastigmine 
In contrast to the other registered AChEIs, 
rivastigmine is a slowly reversible AChEI with a 
similar affinity for AChE and BuChE. Rivastigmine 
has a higher specificity for isoform G1 present in 
brain, thus with a theoretical lower risk of cardio-
inhibitory effects [8], although it is not known 
whether this is of any clinical significance.  Half-life 
of rivastigmine is short (1-2 hours) and it is 40% 
protein bound.  Rivastigmine has a favorable 
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interaction profile since the hepatic CYP450 
isoenzymes  are only minimally involved [8, 10].  
Clinical relevance of cardiac events associated with 
AChEI use 
Data related to clinical events differ in the initial 
prospective studies investigating safety and 
tolerability and effectiveness compared to the later 
published cases and cohort studies in the general 
population. Several reasons explain these 
discrepancies which will further be clarified. 
Findings from trials towards safety, tolerability and 
effectiveness 
All three marketed AChEIs investigated cardiac 
safety and tolerability for their use in AD patients. 
Several studies on their safety, including cardiac 
safety, were published, and we will refer to one 
study for each AChEI. In general, a non-significant 
reduction in heart rate of 2 to 3 beats per minute 
(bpm) was observed [11]. A double blind placebo 
controlled prospective study with donepezil (n=290) 
did not show any significant ECG changes [12] and 
incident bradycardia (HR≤ 60) was 10% compared 
to 7% in the placebo group. One death was reported 
and was unlikely related to treatment with 
donepezil. A double blind placebo controlled trial of 
galantamine in patients with AD did not 
demonstrate any significant effects on heart rate or 
ECG changes [13].  Incident mortality was 1,1% in 
the placebo arm versus 1,4% in the galantamine 
arm. Rivastigmine appeared safe  and did not show 
any significant effect on heart rate, ECG changes or 
mortality in 697 AD patients [14]. In a larger meta-
analysis including 4 double blind placebo controlled 
trials on 2756 patients with AD, rivastigmine did 
not demonstrate any significant changes of heart 
rate, PR or QTc interval [15]. These results suggest a 
very favorable clinical tolerance profile of all three 
AChEIs. A subsequently published subanalysis of 
the Cochrane review [9] demonstrated a significant 
increase of syncope in patients treated with AChEIs 
compared to placebo (odds ratio (OR): 1,9; 95%-CI 
1,09-3,33). A similar increased risk of syncope was 
also observed in a different meta-analysis (OR: 1.53, 
95%-CI 1.02-2.30 [16], without any increase in risk of 
falls and fractures. Though it cannot be concluded 
that the increased risk definitely resulted from 
AChEI therapy, cardio-inhibitory side effects of 
AChEI therapy were potentially involved, which is 
further supported with observational cohort data.   
Observational data 
Several case reports describe a potential association 
between therapy with AChEIs and occurrence of 
bradycardia, atrioventricular block, prolonged QTc 
interval or torsades de pointes [17-22]. A 
population-based study conducted by Park-Wyllie 
et al. investigated the relation between therapy with 
AChEIs and hospital admission for bradycardia 
[23]. The investigators compared 161 patients with 
bradycardia compared to 466 controls without 
bradycardia and concluded that therapy with 
AChEIs doubled the risk of admission for 
bradycardia (adjusted OR: 2,13; 95%-CI 1,29-3,51; 
p=0,003). Two large observational studies 
investigated the incidence of bradycardia, falls, 
syncope and pacemaker implantation in patients 
treated with AChEIs versus a non-treated control 
group. A first retrospective study in 19.803 patients 
treated with a AChEI showed a significantly 
increased incidence of bradycardia (Hazard ratio 
(HR) 1,69; 95%-CI 1,32-2,15), syncope (HR 1,76; 95%-
CI 1,57-1,98), pacemaker implantation (HR 1,49; 
95%-CI 1,12-2,00) and hip fracture (HR 1,18; 95%-CI 
1,04-1,34) [24]. A second large study with 11328 AD 
patients treated with AChEIs demonstrated an 
increased incidence of bradycardia (HR 1,4; 95%-CI 
1,1-1,7), falls (HR 2,6; 95%-CI 1,9-3,5), syncope (HR 
3,7; 95%-CI 2,5-5,5) and pacemaker implantation 
(0,73% versus 0,17%) [25]. Incidence of fractures was 
comparable. These higher incidences of bradycardia 
were reported for all three AChEIs [9, 24, 25] though 
in the study of Hernandez  daily  administration of 
5mg donepezil did not increase the risk of 
bradycardia (HR 1.1; 95% CI 0,85–1,5) compared to 
placebo, whereas higher doses did carry a 
significant risk [25]. Groups treated with 
galantamine or rivastigmine were too small to study 
any dose dependent effects. Also, these higher 
incidences were not associated with an increase in 
mortality. On the contrary, number of deaths was 
lower in the bradycardia group (HR 0,64; 95%-CI 
0,52-0,79). 
In a recent cohort crossover study 3358 Dutch AD 
patients were followed for 8,9 years [26]. The 
analysis was limited to galantamine and 
rivastigmine as donepezil is not authorized in the 
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Netherlands. There were 132 primary 
hospitalizations for atrioventricular block and 17 for 
syncope. Poisson regression showed increased 
incidence densities under AChEI therapy when 
compared to the period before AChEI initiation 
while Cox regression showed numerically increased 
HRs, none of which were statistically significant. 
Although AChEI exposure might increase the risk 
of some adverse cardiac events, the authors 
concluded that the small number of cases limited 
their analysis and that larger study samples would 
be needed.  
In 2013, Nordstrom et al. published a large 
retrospective study of 7073 patients with AD or 
mixed dementia,  in which AChEI use was 
associated with a 34% lower risk for myocardial 
infarction (MI) or death (HR 0,66; 95% CI 0,56–0,78) 
[27]. This reduction persisted when death and MI 
were analyzed separately. The associations were 
stronger with increasing doses. In the 
accompanying editorial it was again emphasized 
that more research was needed [28]. In an earlier 
smaller retrospective study, Sato et al. observed a 
similar association between decreased 
cardiovascular mortality and donepezil use in 156 
patients suffering from AD and vascular dementia 
[29]. Donepezil use was associated with a lower risk 
for cardiovascular (HR 0,54; 95% CI 0.30-0,98) and 
total (HR 0,68; 95% CI 0,46-0,99) mortality.  
In a subsequent small prospective study, donepezil 
did not reduce brain-natriuretic peptide (BNP) 
levels in elderly AD patients without  symptomatic 
heart failure while significantly increasing the QTc 
[30]. No torsades de pointes were seen. The 
investigators did observe a reduction in BNP levels 
in patients with a baseline BNP value of >60pg/ml 
[30]. 
Cholinesterase inhibitors and the heart: friend or 
foe? 
AChEIs indirectly influence peripheral as well as 
central receptors, as a result from the aspecific 
increase in the amount of ACh in the synaptic cleft. 
Cardiac ACh receptors are type M2 muscarinic 
receptors, present within the sinoatrial and 
atrioventricular node and myocardium [4]. 
Activation of these receptors by AChEI could 
theoretically result in negative chronotropic and 
dromotropic effects, clinically manifested as a 
decrease in heart rate, bradycardia or sino-atrial or 
atrioventricular block [17].  
In vivo effects of therapy with AChEIs were 
investigated in animals, where treatment with the 
AChEI  physostigmine resulted in a prolonged 
cardiac cycle length.  In humans, pharmacological 
vagal stimulation would normally result in an 
increase of heart rate variability, a measure for 
cardiac parasympathic activity [31]. Also, local 
vagal neural stimulation by non-pharmacological 
means is currently being investigated in the 
treatment of chronic heart failure, a disease state 
that exhibits an increased sympathic and a 
disordered parasympathic innervation [32, 33]. 
AChEI administration however has resulted in 
reduced heart rate variability in some studies [34, 
35], which could contribute to a higher incidence of 
cardiac adverse events. 
Lowering the heart rate per se does not equal 
negative cardiovascular outcomes. Reduction of 
heart rate is related to better outcomes in patients 
with systolic heart failure in sinus rhythm as has 
been shown for ivabradine [36]. Ivabradine 
decreases heart rate by a selective dose-dependent 
inhibition of the funny current If, which effectively 
slows down the pacing at the sino-atrial node. At 
therapeutic concentrations ivabradine does not 
directly affect other aspects of cardiac function[37]. 
Digoxin, another heart-rate lowering drug has both 
bradycardic and positive inotropic properties. By 
increasing vagal tone it decreases sinus rate and 
slows AV conduction [38]. It has also been 
associated with an increase in heart rate variability, 
as opposed to donepezil. As mentioned above, 
AChEI will only decrease the heart rate by a few 
beats per minute, while ivabradine and digoxin will 
facilitate a larger reduction [39].  
In vivo experiments showed prolonged QTc 
intervals after supratherapeutic doses of 
galantamine [40], and AChEIs were in some cases 
believed to be associated to a prolonged QTc 
interval [18, 19, 21, 22].  
In vitro and animal studies have also shown limited 
cardioprotective effects of AChEI, especially 
donepezil. In high dose, it improved 50 day survival 
in a murine heart failure model and appeared to 
5 
 
have certain anti-inflammatory properties [41, 42]. 
In macrophages, the production of a pro-
inflammatory cytokine was reduced, and in mice 
suffering MI and treated with donepezil,  incidence 
of cardiac rupture during the acute phase of MI 
significantly decreased. Donepezil was also 
revealed to have anti-oxidant and anti-
atherosclerotic properties in male apolipoprotein E 
knockout mice [43]. In summary, although adverse 
drug reactions can occur and are pharmacologically 
plausible, current evidence asks  for a more nuanced 
view on prescribing AChEI in elderly patients. 
Nonspecific stimulation of cholinergic innervation 
could have some cardiovascular benefits, although 
this has not been investigated in adequately 
designed trials. In no way, we advocate the use of 
these drugs in the treatment of cardiovascular 
disease. 
 
Factors putting patients at risk for cardiac effects? 
While generally all AChEIs have a favorable cardiac 
safety profile and incidence of adverse events is 
low,  it could be hypothesized that particular patient 
populations with pre-existing heart disease or 
taking cardio-inhibitory drugs could be at higher 
risk for cardiac adverse events when taking AChEIs. 
Data in this regard are however inconclusive. In the 
study demonstrating an increased incidence of 
hospital admissions for bradycardia in AChEI users 
[23], pre-existing cardiac comorbidity did not 
increase the risk (adjusted OR: 2,25; 95%-CI 1,18-
4,28; p= 0,014) nor did the use of negative 
chronotropic drugs (adjusted OR: 2,34; 95%-CI 1,16-
4,71 p=0,017). On the contrary, in the study of 
Hernandez [25], an elevated risk of a significant 
decrease in heart rate was observed in  patients 
treated with beta-blockers,  as well as in patients 
with a history of MI, hypertension or heart 
failure[25].  
Concerning any influence on QTc, published data 
are reassuring [12, 13, 15, 44], although a few case 
reports have been published describing prolonged 
QTc in patients treated with donepezil, galantamine 
and rivastigmine. No data exist whether 
pharmacodynamic interactions with other QTc-
prolongating drugs might increase the risk for 
cardiac adverse events. Also, it is hard to establish if 
an increased risk of syncope might be a 
consequence of an undiagnosed arrhythmia such as 
torsades de pointes. In 2005, Bordier et al. identified 
a probable cardiovascular cause of syncope (e.g. 
complete AV block) in over two-thirds of patients 
with AD who were treated with donepezil and were 
hospitalised for evaluation of syncope (n =16) [45].  
Therefore, we plea for specific alertness when 
prescribing AChEIs in combination with drugs 
known to induce QTc prolongation Specific 
attention in this regards concerns the prescription of 
neuroleptics, often used in the treatment of 
behavioral disorders in patients simultaneously 
treated with AChEIs and known to prolong QTc-
interval [46]. In any case, alternative non-
pharmacological strategies should be regarded as a 
first line therapy for behavioral symptoms in AD.  
 
Recommendations for practice 
Adverse cardiac effects occur infrequently, but their 
consequences are potentially serious. Therefore, 
possible advantages of starting or continuing 
therapy with AChEIs should be weighed against 
potential risks. This estimation is not always 
straightforward, since effect sizes of clinical benefits 
of AChEI therapy vary and adverse effects are 
difficult to predict. Special consideration should go 
to patients at increased risk. Though no generally 
accepted guidelines for monitoring exist, some 
authors recommend to systematically obtain an 
ECG before therapy with AChEIs is started, in order 
to have baseline information available and for 
comparison purposes [47];  the evidence for this is  
however limited. Nevertheless, we do recommend 
special attention for cardiac side effects in all 
patients treated with AChEIs, which can be offered 
as suggested by a an adapted clinical protocol 
proposed by Rowland et al. [48] (Figure 1). With 
each patient contact (including before therapy start), 
a history-taking focusing on symptoms of cardiac 
side effects such as dizziness, falls, syncope is 
required, followed by registration of the heart 
frequency. After start of therapy, monthly follow-up 
is preferred during the titration phase until a stable 
dose has been reached followed by a 6-month 
interval control. If the patients’ history is suggestive 
for cardiac side effects, and/or if heart rate 
6 
 
frequency is <50 bpm, further cardiac evaluation is 
recommended. With a heart rate between 50 and 60 
bpm,  alertfullness is required independent of the 
occurrence of any symptoms. While for galantamine 
and rivastigmine it is suspected but unknown 
whether a dose reduction would decrease the risk of 
cardiac adverse events, a lower dose (5mg) of 
donepezil decreased the risk of side effects to that of 
a control population [25]. 
In the presence of a history of bradycardia, 
arrhythmia or known QTc prolongation, or when 
taking drugs with negative chronotropic effects or 
with high risk of prolonging the QTc interval, we 
recommend a renewed history-taking at each visit 
and ECG monitoring before and during therapy, 
though no consensus guideline exist. In our 
experience and as suggested by Rowland et al. [48], 
a first-degree heart block is no contraindication for 
therapy with AChEIs but a more intensive clinical 
and ECG monitoring is advised. In case of a second-
degree heart block, and certainly for a Mobitz type 
II, starting or continuing therapy should only be 
done after specialist advise.  
Lastly, certain drugs might influence the 
pharmacokinetics of donepezil and galantamine by 
interacting with the hepatic CYP450 system (Table 
1).  Inhibition of CYP2D6 and/or CYP3A4 could at 
least theoretically result in a higher exposure for 
both drugs, potentially leading to adverse drug 
events while induction of these hepatic isoenzymes 
would result in a lower efficacy. Relevant data 
however are scarce. AChEIs should not be 
perceived as drugs with a narrow therapeutic index, 
unlike digoxin or warfarin. Nevertheless, although 
the clinical relevance of these interactions still needs 
to be determined, they are as a rule avoidable and in 
that sense interactions should be taken into account 
when monitoring AChEI therapy [49].  
 
Conclusion 
AChEIs are widely used and prescribed in the 
treatment of AD, and are generally safe to use also 
in an elderly population. Both beneficial and 
adverse cardiac effects have been related to AChEIs 
therapy, but serious adverse events related to this 
therapy are infrequent. Nevertheless, prescribers 
should be aware of the possible consequences of 
their prescriptions, and in the case of AChEIs 
negative chronotropic and dromotropic effects 
could occur. While several RCTs did not find any 
significant cardiac adverse effect, population based 
open label studies reported the infrequent 
occurrence of bradycardia, syncope, falls and 
pacemaker implantation, but use of AChEIs was 
also associated with  a decreased risk ofMI or 
mortality. Because of its G1 selectivity, rivastigmine 
has a higher affinity for cerebral receptors; clinical 
evidence of a decreased cardiac risk compared to 
donepezil and galantamine is however not 
available. Patients diagnosed with cardiac disease or 
taking drugs with negative chronotropic of 
dromotropic effects are potentially at higher risk, 
though available data do not support this 
uniformly.  
Prescribers of therapy with AChEIs should pay 
attention to clinical symptoms of cardiac adverse 
effects, and monitor the heart rate of their patients. 
In selected cases, it could be reasonable to perform 
ECG monitoring though no consensus  exists. In 
some cases the advantages of starting or continuing 
therapy should be outweighed against potential 
disadvantages.  
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Table 1. Commonly used inhibitors of cytochrome P450 enzymes (CYP2D6 and CYP3A4) in older persons. 
 
CYP3A4 Inhibitors CYP2D6 Inhibitors 
Diltiazem Fluoxetine 
Verapamil Haloperidol 
Itraconazole Paroxetine 
Amiodarone 
 
Ketoconazole  
Clarithromycin  
Erythromycin  
Grapefruit juice 
Amiodarone 
Amlodipine 
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Figure 1. Clinical protocol for initiation or continuation of AChEI therapy in asymptomatic and symptomatic patients (adapted 
from [48]). 
 
